VanderMolen L A, Duffey P L, Cossman J, Jaffe E S, Longo D L
Biological Response Modifiers Program, NCI-Frederick Cancer Research Facility, MD 21701.
Am J Hematol. 1990 May;34(1):15-20. doi: 10.1002/ajh.2830340105.
The indolent follicular and diffuse lymphomas are neoplasms of B-cell origin. In several other B-cell neoplastic disorders, including multiple myeloma, hairy cell leukemia, and chronic lymphocytic leukemia, the light chain isotype of the surface immunoglobulin has been reported to have prognostic significance. Patients with tumors expressing lambda light chains usually fare more poorly than those with kappa light chain-bearing tumours. We analyzed the clinical data and immunologic phenotype of 101 patients with indolent lymphoma. Eighty-nine of the 101 patients demonstrated surface immunoglobulin of only one light chain type (kappa-47, lambda-42). Patients in both groups were matched for known prognostic factors. There were no significant differences in disease-free survival or overall survival between the two groups or within histologic subtypes. These results indicate that the immunologic light chain phenotype in indolent lymphoma, unlike other B-cell neoplasms, is not a prognostic indicator of survival.
惰性滤泡性淋巴瘤和弥漫性淋巴瘤是B细胞起源的肿瘤。在其他几种B细胞肿瘤性疾病中,包括多发性骨髓瘤、毛细胞白血病和慢性淋巴细胞白血病,据报道表面免疫球蛋白的轻链同种型具有预后意义。表达λ轻链的肿瘤患者通常比携带κ轻链肿瘤的患者预后更差。我们分析了101例惰性淋巴瘤患者的临床数据和免疫表型。101例患者中有89例仅表现出一种轻链类型的表面免疫球蛋白(κ链47例,λ链42例)。两组患者的已知预后因素相匹配。两组之间或组织学亚型内的无病生存期或总生存期均无显著差异。这些结果表明,与其他B细胞肿瘤不同,惰性淋巴瘤的免疫轻链表型不是生存的预后指标。